Kava Monograph

References

• Russmann S, Lauterburg B H, Helbling A. Kava hepatotoxicity. Ann Intern Med 2001; 135(1)68–69
   PubMed Web of Science ®Google Scholar
• Escher M, Desmeules J, Giostra E, et al. Hepatitis associated with Kava, a herbal remedy for anxiety. BMJ 2001; 322(7279)139
   PubMed Web of Science ®Google Scholar
• Kraft M, Spahn T W, Menzel J, et al. [Fulminant liver failure after administration of the herbal antidepressant Kava-Kava]. Dtsch Med Wochenschr 2001; 126(36)970–972
   PubMed Web of Science ®Google Scholar
• Center for Food Safety and Applied Nutrition (US Food and Drug Administration). Kava-containing dietary supplements may be associated with severe liver injury, (document issued March 25, 2002)
   Google Scholar
• Center for Food Safety and Applied Nutrition (US Food and Drug Administration). Letter to health care professionals: FDA issues consumer advisory that kava products may be associated with severe liver injury, (document issued March 25, 2002). Contact information for FDA Medwatch program: 1-800-332-1088
   Google Scholar
• De Leo V, La Marca A, Lanzetta D, et al. [Assessment of the association of Kava-Kava extract and hormone replacement therapy in the treatment of postmeno-pause anxiety]. Minerva Ginecol 2000; 52(6)263–267
   PubMedGoogle Scholar
• Cawte J. Parameters of kava used as a challenge to alcohol. Aust N Z J Psychiatry 1986; 20(1)70–76
   PubMed Web of Science ®Google Scholar
• Gleitz J, Friese J, Beile A, et al. Anticonvulsive action of (+/2)-kavain estimated from its properties on stimulated synaptosomes and Na+ channel receptor sites. Eur J Pharmacol 1996; 315(1)89–97
   PubMed Web of Science ®Google Scholar
• Schmitz D, Zhang C L, Chatterjee S S, et al. Effects of methysticin on three different models of seizure like events studied in rat hippocampal and entorhinal cortex slices. Naunyn Schmiedebergs Arch Pharmacol 1995; 351(4)348–355
   PubMed Web of Science ®Google Scholar
• Baum S S, Hill R, Rommelspacher H. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. Prog Neuro-psychopharmacol Biol Psychiatry 1998; 22(7)1105–1120
   PubMed Web of Science ®Google Scholar
• Steiner G G. The correlation between cancer incidence and kava consumption. Hawaii Med J 2000; 59(11)420–422
   PubMedGoogle Scholar
• Singh Y N. Effects of kava on neuromuscular transmission and muscle contractility. J Ethnopharmacol 1983; 7(3)267–276
   PubMed Web of Science ®Google Scholar
• Kinzler E, Kromer J, Lehmann E. [Effect of a special kava extract in patients with anxiety-, tension-, and excitation states of non-psychotic genesis. Double blind study with placebos over 4 weeks]. Arzneimittelforschung 1991; 41(6)584–588
   PubMedGoogle Scholar
• Warnecke G. [Psychosomatic dysfunctions in the female climacteric. Clinical effectiveness and tolerance of Kava Extract WS 1490]. Fortschr Med 1991; 109(4)119–122
   PubMedGoogle Scholar
• Volz H P, Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety dis-orders-a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry 1997; 30(1)1–5
   PubMed Web of Science ®Google Scholar
• Pittler M H, Ernst E. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. J Clin Psychopharmacol 2000; 20(1)84–89
   PubMed Web of Science ®Google Scholar
• Mathews J D, Riley M D, Fejo L, et al. Effects of the heavy usage of kava on physical health: summary of a pilot survey in an aboriginal community. Med J Aust 1988; 148(11)548–555
   PubMed Web of Science ®Google Scholar
• Singh Y N. Kava: an overview. J Ethnopharmacol 1992; 37(1)13–45
   PubMed Web of Science ®Google Scholar
• Spillane P K, Fisher D A, Currie B J. Neurological manifestations of kava intoxication. Med J Aust 1997; 167(3)172–173
   PubMed Web of Science ®Google Scholar
• Meyer H G. Pharmakologie der wirksamen prinzipien de kawarhizoms (Piper methysticum, Forst.). Arch Int Pharmacodyn Ther 1962; 138: 505–536
   PubMedGoogle Scholar
• Jappe U, Franke I, Reinhold D, et al. Sebotropic drug reaction resulting from kava-kava extract therapy: a new entity?. J Am Acad Dermatol 1998; 38(1)104–106
   PubMed Web of Science ®Google Scholar
• Schmidt P, Boehncke W H. Delayed-type hypersensitivity reaction to kava-kava extract. Contact Dermatitis 2000; 42(6)363–364
   PubMed Web of Science ®Google Scholar
• Suss R, Lehmann P. [Hematogenous contact eczema caused by phytogenic drugs exemplified by kava root extract]. Hautarzt 1996; 47(6)459–461
   PubMedGoogle Scholar
• Siegers C P, Honold E, Krall B, et al. Results of the drug monitoring L 1090 with Laitan capsules. Arztl Forsch 1992; 39: 7–11
   Google Scholar
• Norton S A, Ruze P. Kava dermopathy. J Am Acad Dermatol 1994; 31(1)89–97
   PubMed Web of Science ®Google Scholar
• Ruze P. Kava-induced dermopathy: a niacin deficiency?. Lancet 1990; 335(8703)1442–1445
   PubMed Web of Science ®Google Scholar
• Keller F, Klohs M. A review of the chemistry and pharmacology of the constituents of Piper methysticum. Lloydia 1963; 26: 1–15
   Google Scholar
• Holm E, Staedt U, Heep J, et al. [The action profile of D,L-kavain. Cerebral sites and sleep-wakefulness-rhythm in animals]. Arzneimittelforschung 1991; 41(7)673–683
   PubMed Web of Science ®Google Scholar
• Munte T F, Heinze H J, Matzke M, et al. Effects of oxazepam and an extract of kava roots (Piper methysticum) on event-related potentials in a word recognition task. Neuropsychobiology 1993; 27(1)46–53
   PubMed Web of Science ®Google Scholar
• Gessner B, Cnota P. Extract of the kava-kava rhizome in comparison with diaz-epam and placebo. Z Phytother 1994; 15(1)30–37
   Google Scholar
• Johnson D, Frauendorf A, Stecker K, et al. Neurophysiological active profile and tolerance of kava extract WS 1490, A pilot study with randomized evaluation. TW Neurolgie Psychiatrie 1991; 5(6)349–354
   Google Scholar
• Herberg K W. Driving ability after intake of kava special extract WS 1490, a double-blind, placebo-controlled study with volunteers. Zeitschrift für Allgemeinmedizin 1991; 13: 842–846
   Google Scholar
• Herberg K W. [Effect of Kava-Special Extract WS 1490 combined with ethyl alcohol on safety-relevant performance parameters]. Blutalkohol 1993; 30(2)96–105
   PubMedGoogle Scholar
• Almeida J C, Grimsley E W. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med 1996; 125(11)940–941
   PubMed Web of Science ®Google Scholar
• Prescott J, Jamieson D, Emdur N, et al. Acute effects of kava on measures of cognitive performance, physiological function and mood. Drug Alc Rev 1993; 12: 49–58
   PubMedGoogle Scholar
• Saletu B, Grünberger J, Linzmayer L, et al. EEG-brain mapping, psychometric and psychophysiological studies on central effects of kavain-a kava plant derivative. Hum Psychopharm 1989; 4: 169–190
   Google Scholar
• Schelosky L, Raffauf C, Jendroska K, et al. Kava and dopamine antagonism. J Neurol Neurosurg Psychiatry 1995; 58(5)639–640
   PubMed Web of Science ®Google Scholar
• Garner L F, Klinger J D. Some visual effects caused by the beverage kava. J Ethnopharmacol 1985; 13(3)307–311
   PubMed Web of Science ®Google Scholar
• Strahl S, Ehret V, Dahm H H, et al. [Necrotizing hepatitis after taking herbal remedies]. Dtsch Med Wochenschr 1998; 123(47)1410–1414
   PubMed Web of Science ®Google Scholar
• Douglas W. The effects of heavy usage of kava on physical health. Med J Australia 1988; 149: 341–342
   PubMed Web of Science ®Google Scholar
• Stafford N. Germany may ban kava kava herbal supplement. Reuter's News Service Germany November 19, 2001
   Google Scholar
• Scherer J. Kava-kava extract in anxiety disorders: an outpatient observational study. Adv Ther 1998; 15(4)261–269
   PubMed Web of Science ®Google Scholar
• Donadio V, Bonsi P, Zele I, et al. Myoglobinuria after ingestion of extracts of guarana, Ginkgo biloba and kava. Neurol Sci 2000; 21(2)124
   PubMed Web of Science ®Google Scholar
• Gleitz J, Beile A, Wilkens P, et al. Antithrombotic action of the kava pyrone (+)-kavain prepared from Piper methysticum, on human platelets. Planta Med 1997; 63(1)27–30
   PubMed Web of Science ®Google Scholar
• Jamieson D D, Duffield P H, Cheng D, et al. Comparison of the central nervous system activity of the aqueous and lipid extract of kava (Piper methysticum). Arch Int Pharmacodyn Ther 1989; 301: 66–80
   PubMedGoogle Scholar
• Jamieson D D, Duffield P H. Positive interaction of ethanol and kava resin in mice. Clin Exp Pharmacol Physiol 1990; 17(7)509–514
   PubMed Web of Science ®Google Scholar
• Davies L P, Drew C A, Duffield P, et al. Kava pyrones and resin: studies on GABAA, GABAB and benzodiazepine binding sites in rodent brain. Pharmacol Toxicol 1992; 71(2)120–126
   PubMedGoogle Scholar
• Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched extract from Piper methysticum, as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology (Berl) 1994; 116(4)469–474
   PubMed Web of Science ®Google Scholar
• Uebelhack R, Franke L, Schewe H J. Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum, Forster (kava-kava). Pharmaco-psychiatry 1998; 31(5)187–192
   PubMed Web of Science ®Google Scholar
• Murphy J M. Preoperative considerations with herbal medicines. AORN J 1999; 69(1)173–8, 180
   PubMedGoogle Scholar
• Beckman S E, Sommi R W, Switzer J. Consumer use of St. John's wort: a survey on effectiveness, safety, and tolerability. Pharmacotherapy 2000; 20(5)568–574
   PubMed Web of Science ®Google Scholar
• Duffield A M, Lidgard R O, Low G K. Analysis of the constituents of Piper methysticum, by gas chromatography methane chemical ionization mass spectrometry. New constituents of kava resin. Biomed Environ Mass Spectr 1986; 13: 305–313
   Google Scholar
• Duffield A M, Lidgard R O. Analysis of kava resin by gas chromatography and electron impact and methane negative ion chemical ionization mass spectrometry. New trace constituents ofkava resin. Biomed Environ Mass Spectr 1986; 13: 621–626
   Google Scholar
• Duve R N. Gas-liquid chromatographic determination of major constituents of Piper methysticum. Analyst 1981; 106: 160–165
   Web of Science ®Google Scholar
• Klohs M W, Keller F, Williams R E, et al. A chemical and pharmacological investigation of Piper methysticum, Forst. J Med Pharm Chem 1959; 1(1)95–103
   PubMedGoogle Scholar
• Smith R M. Kava lactones in Piper methysticum, from Fiji. Phytochemistry 1983; 22: 1055–1056
   Web of Science ®Google Scholar
• Smith R M, Thakrar H, Arowolo A, et al. High-performance liquid chromatog-raphy of kava lactones from Piper methysticum. J Chromatography 1984; 283: 303–308
   Web of Science ®Google Scholar
• Young R L, Hylin J W, Plucknett D L, et al. Analysis for kawa pyrones in extracts of piper methysticum. Phytochemistry 1966; 5: 795–798
   Web of Science ®Google Scholar
• Brüggemann F, Meyer H J. Die analgetische wirkung der Kawa-inhaltsstoffe dihydrokawain und dihydromethysticin. Arzneimittelforschung 1963; 13: 407–409
   PubMed Web of Science ®Google Scholar
• Hänsel R. Characterization and physiological activity of some Kawa constituents. Pacific Science 1968; 22: 293–313
   Web of Science ®Google Scholar
• Kretzschmar R, Meyer H J. [Comparative studies on the anticonvulsant activity of the pyrone compounds of Piper methysticum, Forst]. Arch Int Pharmacodyn Ther 1969; 177(2)261–277
   PubMedGoogle Scholar
• Kretzschmar R, Meyer H J, Teschendorf H J. Strychnine antagonistic potency of pyrone compounds of the kavaroot (Piper methysticum, Forst.). Experientia 1970; 26(3)283–284
   PubMedGoogle Scholar
• Kretzschmar R, Teschendorf H J, Ladous A, et al. On the sedative action of the kava rhizome (Piper methyst.). Acta Pharmacol Toxicol 1971; 29(4)26
   Google Scholar
• Meyer H J. [Spasmolytic effect of dihydromethysticin, a constituent of Piper methysticum, Forst]. Arch Int Pharmacodyn Ther 1965; 154(2)449–467
   PubMedGoogle Scholar
• Meyer H J, Meyer-Burg J. Hemmung des elektrokrampfes durch die kawa-pyrone dihydromethysticin und dihydrokawain. Arch Int Pharmacodyn 1964; 148(1–2)97–110
   PubMedGoogle Scholar
• Singh Y, Blumenthal M. Kava: an overview. Distribution, mythology, botany, culture, chemistry and pharmacology of the South Pacific's most revered herb. Herbal Gram 1997; 39(Suppl 1)34–56
   Google Scholar
• Backhauss C, Krieglstein J. Extract of kava (Piper methysticum) and its methysticin constituents protect brain tissue against ischemic damage in rodents. European Journal of Pharmacology 1992; 215(2–3)265–269
   PubMed Web of Science ®Google Scholar
• Kleiser B, Diepers M, Wagner N, et al. Treatment of intracerebral hematomas with kava in rats. Neurology 1998; 50(4)a398
   PubMed Web of Science ®Google Scholar
• Walden J, von Wegerer J, Winter U, et al. Effects of kawain and dihydro-methysticin on field potential changes in the hippocampus. Prog Neuropsychopharm-acol Biol Psychiatry 1997; 21(4)697–706
   PubMed Web of Science ®Google Scholar
• Walden J, von Wegerer J, Winter U, et al. Actions of kavain and dihydro-methysticin on ipsapirone-induced field potential changes in the hippocampus. Human Psychopharm 1997; 12: 265–270
   Web of Science ®Google Scholar
• Gleitz J, Gottner N, Ameri A, et al. Kavain inhibits non-stereospecifically verat-ridine-activated Na+ channels. Planta Med 1996; 62: 580–581
   PubMed Web of Science ®Google Scholar
• Magura E I, Kopanitsa M V, Gleitz J, et al. Kava extract ingredients, (+)-methy-sticin and (+/2)-kavain inhibit voltage-operated Na(+)-channels in rat CA1 hippocampal neurons. Neuroscience 1997; 81(2)345–351
   PubMed Web of Science ®Google Scholar
• Seitz U, Schule A, Gleitz J. [3H]-monoamine uptake inhibition properties of kava pyrones. Planta Med 1997; 63(6)548–549
   PubMed Web of Science ®Google Scholar
• Emser W, Bartylla K. Improvement of sleep quality. Effect of kava extract WS 1490 on the sleep pattern in healthy subjects. Neurologie/Psychiatrie 1991; 5(11)636–642
   Google Scholar
• Gleitz J, Beile A, Peters T. (+/2)-kavain inhibits the veratridine- and KCl-in-duced increase in intracellular Ca2+ and glutamate-release of rat cerebrocortical synaptosomes. Neuropharmacology 1996; 35(2)179–186
   PubMed Web of Science ®Google Scholar
• Boonen G, Ferger B, Kuschinsky K, et al. In vivo effects of the kavapyrones (+)-dihydromethysticin and (+/2) kavain on dopamine, 3,4-dihydroxyphenylacetic acid, serotonin and 5-hydroxyindoleacetic acid levels in striatal and cortical brain regions. Planta Med 1998; 64(6)507–510
   PubMed Web of Science ®Google Scholar
• Buckley J P, Furgiuele A R, O'Hara M J. Pharmacology of kava. Ethnopharm Search Psych Drugs 1967; 1: 141–151
   Google Scholar
• Furgiuele A R, Kinnard W J, Aceto M D, et al. Central activity of aqueous extracts of Piper methysticum, (kava). J Pharm Sci 1965; 54: 247–252
   PubMed Web of Science ®Google Scholar
• Jamieson D D, Duffield P H. The antinociceptive actions of kava components in mice. Clin Exp Pharmacol Physiol 1990; 17(7)495–507
   PubMed Web of Science ®Google Scholar
• Duffield P H, Jamieson D. Development of tolerance to kava in mice. Clin Exp Pharmacol Physiol 1991; 18(8)571–578
   PubMed Web of Science ®Google Scholar
• Duffield A M, Jamieson D D, Lidgard R O, et al. Identification of some human urinary metabolites of the intoxicating beverage kava. J Chromatogr 1989; 475: 273–281
   PubMed Web of Science ®Google Scholar
• Bhate H, Gerster G, Gracza E. Orale Prämedikation mit Zubereitungen aus Piper methysticum bei operativen Eingriffen in Epiduralanästhesie. Erfahrungsheilkunde 1989; 6: 339–345
   Google Scholar
• Lehmann E, Kinzler E, Friedemann J. Efficacy of a special Kava extract (Piper methysticum) in patients with states of anxiety, tension and excitedness of non-mental origin-a double-blind placebo-controlled study of four weeks treatment. Phytomedi-cine 1996; 3(2)113–119
   PubMed Web of Science ®Google Scholar
• Singh N N, Ellis C R, Sharp I, et al. A 4-week randomized, double-blind, placebo-controlled study to investigate the effectiveness and safety of Kavatrol was conducted in a non-clinical sample with anxiety and stress. Natrol data 1977
   Google Scholar
• Malsch U, Kieser M. Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines. Psychopharm 2001; 157(3)277–283
   Web of Science ®Google Scholar
• Volz H P. Die anxiolytische wirksmkeit von Kava-spezialextrakt WS 1490 unter langzeittherapie-eine randomisierte doppelblindstudie. Zeit Phytother 1992; 5(6)214–222
   Google Scholar
• De L V, La Marca A, Morgante G, et al. Evaluation of combining kava extract with hormone replacement therapy in the treatment of postmenopausal anxiety. Maturitas 2001; 39(2)185–188
   PubMed Web of Science ®Google Scholar
• Lehmann E, Klieser E, Klimke A, et al. The efficacy of Cavain in patients suffering from anxiety. Pharmacopsychiatry 1989; 22(6)258–262
   PubMed Web of Science ®Google Scholar
• Lindenberg D, Pitule-Schodel H. [D,L-kavain in comparison with oxazepam in anxiety disorders. A double-blind study of clinical effectiveness]. Fortschr Med 1990; 108(2)49–53
   PubMedGoogle Scholar
• Wheatley D. Kava and valerian in the treatment of stress-induced insomnia. Phytother Res 2001; 15: 549–551
   PubMed Web of Science ®Google Scholar
• Woelk H, Kapoula O, Lehrl S, et al. [Treatment of patients suffering from anxiety-double-blind study: kava special extract versus benzodiazepines]. Z Allg Med 1993; 69: 271–277
   Google Scholar
• Pfeiffer C C, Murphree H B, Goldstein L. Effect of kava in normal subjects and patients. Psychopharmacol Bull 1967; 4(3)12
   PubMedGoogle Scholar
• Jadad A R, Moore R A, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin. Trials 1996; 17(1)1–12
   PubMedGoogle Scholar